财报披露
Galmed(GLMD)06-06 04:25
$Galmed(GLMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001493152-24-022747 Act: 34 Size: 171 KB 网页链接
简介:Galmed Pharmaceuticals Ltd.于2013年7月31日在以色列成立,它是一家以色列的私人公司。公司是一家临床生物制药企业,专注于开发一种新颖、每天一次并且能够口服的用于治疗肝脏疾病及胆固醇结实的药物,并将该药物商业化。
今开:0.2988 | 昨收:0.2933 |
最高:0.2988 | 最低:0.2936 |
涨停价: | 跌停价: |
总市值:1877738 |
Galmed(GLMD)06-06 04:25
$Galmed(GLMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001493152-24-022747 Act: 34 Size: 171 KB 网页链接
Galmed(GLMD)07-19 04:35
$Galmed(GLMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001493152-24-028342 Act: 34 Size: 16 KB 网页链接
Galmed(GLMD)05-31 04:35
$Galmed(GLMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001493152-24-021989 Act: 34 Size: 239 KB 网页链接
Galmed(GLMD)07-11 20:55
$Galmed(GLMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001493152-24-026889 Act: 34 Size: 16 KB 网页链接
F1watch2023-07-14 05:20
F-1/A - Galmed Pharmaceuticals Ltd. (0001595353) (Filer) Filed: 2023-07-13 AccNo: 0001493152-23-024507 Size: 822 KB 网页链接查看全文
F1watch2023-07-13 05:40
F-1/A - Galmed Pharmaceuticals Ltd. (0001595353) (Filer) Filed: 2023-07-12 AccNo: 0001493152-23-024354 Size: 1 MB 网页链接查看全文
F1watch2023-06-28 20:40
F-1/A - Galmed Pharmaceuticals Ltd. (0001595353) (Filer) Filed: 2023-06-28 AccNo: 0001493152-23-022693 Size: 1 MB 网页链接查看全文
F1watch2023-06-17 04:20
F-1 - Galmed Pharmaceuticals Ltd. (0001595353) (Filer) Filed: 2023-06-16 AccNo: 0001493152-23-021672 Size: 1 MB 网页链接查看全文
蹊之美股生物医药2021-11-02 22:10
作者:王医生
微信公众号:蹊之美股生物医药 / CaesarBiotech
标的公司:Galmed Pharmaceuticals Ltd.(NASDAQ:GLMD)
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD)是一家临床阶段的肝脏、代谢和炎症疾病生物制药公司,今天宣布了ARMOR 3期研究开放标签部分的前16名患者接受预定的...查看全文
蹊之美股生物医药2021-08-03 23:10
Gainers:
Infinity Pharmaceuticals (NASDAQ:INFI)+38%
Exicure (NASDAQ:XCUR) +34%
Ra Medical Systems (NYSE:RMED) +18%
Galmed Pharmaceuticals (NASDAQ:GLMD) +17%
Lava Therapeutics (NASDAQ:LVTX) +5%
Losers:
Immunovant (NASDAQ:IMVT) -26%...查看全文
鲜克有终72021-06-07 17:55
$Galmed(GLMD)$ 例行减仓查看全文
美通社2021-04-03 23:45
中国苏州和美国马里兰州罗克维尔市2021年4月2日 /美通社/ -- 致力于在肿瘤、乙肝及与衰老相关疾病等治疗领域开发创新药物的处于临床阶段的研发企业——亚盛医药(6855.HK)日前宣布,公司任命知名肿瘤学专家David Sidransky博士为独立非执行董事,该任命自2021年3月31日起生效。
Sidransky博士...查看全文
洛其飞2021-02-15 11:50
$Galmed(GLMD)$ 目前全球领先的NASH新药研发公司,如果今年能第一家取得FDA该类新药的审批,妥妥超过nvax去年的涨幅,持续关注nash类新药研发进展。查看全文
$Galmed(GLMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001493152-24-028342 Act: 34 Size: 16 KB 网页链接
$Galmed(GLMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001493152-24-026889 Act: 34 Size: 16 KB 网页链接
$Galmed(GLMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001493152-24-022747 Act: 34 Size: 171 KB 网页链接
$Galmed(GLMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001493152-24-021989 Act: 34 Size: 239 KB 网页链接
$Galmed(GLMD)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001493152-24-013203 Act: 34 Size: 9 MB 网页链接
$Galmed(GLMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001493152-24-010476 Act: 34 Size: 16 KB 网页链接
$Galmed(GLMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001493152-24-010019 Act: 34 Size: 32 KB 网页链接
$Galmed(GLMD)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-023435 Act: 34 Size: 61 KB 网页链接
$Galmed(GLMD)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000921895-24-000447 Act: 34 Size: 266 KB 网页链接
$Galmed(GLMD)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001493152-24-005902 Act: 34 Size: 97 KB 网页链接